2-FDCK

2-FDCK (2-fluorodeschloroketamine, also written 2F-DCK) is a synthetic dissociative of the arylcyclohexylamine class, closely related to ketamine — its structure is ketamine with the chlorine atom replaced by fluorine. It was first synthesized as part of research into ketamine analogues and appeared on the online "research chemical" market around 2016-2017, marketed as a legal ketamine substitute after another analogue (deschloroketamine) had been introduced. It is usually a powder that people snort or swallow. It has been detected in forensic, driving-under-the-influence, and wastewater samples in Europe and elsewhere.

2-FDCK is presumed to act like ketamine — as an antagonist at the NMDA glutamate receptor, the mechanism shared by ketamine, PCP, and MXE that produces the dissociative state. This is an important caveat: much of what is said about 2-FDCK's pharmacology is inferred from its close structural similarity to ketamine and from users' reported effects, rather than established by direct study. Its detailed receptor pharmacology in humans has not been well characterized, and it is best understood as "ketamine-like" by analogy rather than by evidence.

Reported effects are described as similar to ketamine's: dissociation and detachment from body and surroundings, sedation, pain relief, altered perception, and at higher doses an immersive dissociative state. Because reliable human data are scarce, most descriptions come from user reports and isolated clinical case reports rather than controlled studies, so the picture of its effects — and how they differ from ketamine's — is incomplete.

The central risk with 2-FDCK is how little is known about it. As a dissociative it is expected to impair coordination and judgment, raising the risk of injury, and to carry the dependence potential common to NMDA-antagonist dissociatives, with cross-tolerance to ketamine and MXE. Because product strength varies and its potency relative to ketamine is not well established, dosing is uncertain and overdose is a real risk. Case reports document intoxications involving 2-FDCK, often alongside other drugs. Combining it with other depressants such as alcohol, benzodiazepines, or opioids is especially dangerous. The honest summary is that its long-term effects and safety profile in humans are essentially unknown.